CBT-295

Kundenbewertung

Based on 1 Customer Validation

CBT-295 is an orally active autotaxin (ATX) inhibitor. CBT-295 exhibits a significant reduction in inflammatory cytokines like TGF-β, TNF-α and IL-6 levels, also reduced bile duct proliferation marker CK-19 and lowered liver fibrosis. The reversal of liver fibrosis with CBT-295 led to a reduction in blood and brain ammonia levels. CBT-295 also reduced neuroinflammation induced by ammonia. CBT-295 is promising for research of liver cirrhosis and associated encephalopathy.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • Reinheit: 99.34%
  • CAS. Nr.: 1623794-90-0
  • Formel: C18H20ClN3O
  • Molecular Weight:329.82
  • Speicherung:

    4°C, sealed storage, away from moisture and light

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

  • Biologische Aktivität
  • Chemical Information
  • Lösungsmittel & Löslichkeit
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs

Alle TGF-beta/Smad Isoform-spezifische Produkte anzeigen

More

Alle Interleukin Related Isoform-spezifische Produkte anzeigen

More
100 mg

Angebot einholen Auf Lager

Please select quantity
Amount: USD 0.00